Oct 03, 2016 12:01 pm UTC| Business
NEW YORK, Oct. 03, 2016 -- Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the first patient has been dosed in a Phase 1/2 clinical study of CK-101, its...
K2M Group Holdings, Inc. to Release Third Quarter 2016 Financial Results on November 2nd
Oct 03, 2016 12:01 pm UTC| Business
LEESBURG, Va., Oct. 03, 2016 -- K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex...
BroadSoft Technology Integrated in One Talk℠ by Verizon: First U.S. Business 4G VoLTE Offering
Oct 03, 2016 12:01 pm UTC| Business
GAITHERSBURG, Md., Oct. 03, 2016 -- BroadSoft, Inc. (NASDAQ:BSFT), a global unified communication software as a service (UCaaS) leader, today announced that its BroadWorks® platform is integrated in One Talk by Verizon...
Argos Therapeutics to Participate in 2016 Cell & Gene Meeting on the Mesa
Oct 03, 2016 12:01 pm UTC| Business
DURHAM, N.C., Oct. 03, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis®...
Synaptics TouchView TDDI, ClearForce Featured on Xiaomi Mi 5s, Mi 5s Plus Smartphones
Oct 03, 2016 12:01 pm UTC| Business
SAN JOSE, Calif., Oct. 03, 2016 -- Synaptics Incorporated (NASDAQ:SYNA), the leading developer of human interface solutions, today announced that Xiaomi, one of the world’s largest mobile manufacturers, selected its...
Oct 03, 2016 12:01 pm UTC| Business
Company Reaches Agreement with Regulatory Agencies on Key Elements of Phase 3 Program Phase 3 Program Expected to Begin by Year-end SAN DIEGO, Oct. 03, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage...
Oct 03, 2016 12:00 pm UTC| Business
DUBLIN, Ireland and TREVOSE, Pa., Oct. 03, 2016 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global biopharmaceutical company focused on the development and commercialization of novel therapies for rare diseases,...